Accès ouvert
2026
article
OpenAlex
Elwira Szychot, Jan-Marius Wedig, Kyra Druivenga, Moatasem El-Ayadi et autres
Abstract Structured physical exercise programs (PEPs) in pediatric oncology have shown benefits for physical, psychosocial, and cognitive outcomes, yet their integration into routine care varies globally. This study explores health care professionals' perceptions of PEPs across European, North African, and Arab pediatric …
gb, pl, de, Égypte, at, it, jo, Maroc, sa, es, nl, ch, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Julie A S Lammers, Jacob S Rozowsky, Friso Calkoen, Thijs J M van den Broek et autres
BACKGROUND: Pilocytic astrocytomas (PAs) are the most common pediatric central nervous system tumors, which present with limited genetic but significant clinical heterogeneity. Current treatment strategies are partly effective, but tumors often progress, and patients experience long-term side effects, highlighting the need for …
nl, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Raoull Hoogendijk, Riccardo Capocaccia, Jasper van der Lugt, Mariëtte E.G. Kranendonk et autres
nl, it
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Thijs J M van den Broek, Raoull Hoogendijk, Mariëtte E.G. Kranendonk, Julie A S Lammers et autres
Abstract Background Pediatric-type diffuse high-grade gliomas (pHGGs) are a leading cause of pediatric cancer-related mortality. Although immunotherapy offers a promising treatment avenue, clinical responses in pHGG patients remain limited. A detailed understanding of the tumor immune microenvironment (TIME) is essential for advancing …
nl
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Lotte A. de Koning, Daniel Aaron Vazquez-Matias, Wissam Beaino, Daniëlle J. Vugts et autres
The field of Alzheimer’s disease (AD) drug development is rapidly changing, with two anti-amyloid monoclonal antibodies (mAbs) having received Food and Drug Administration (FDA) approval, additionally many compounds are in the pipeline. A major obstacle for novel AD therapeutics is the blood-brain …
nl
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Fasco van Ommen, Toon Van Genechten, Mirjam E. Willemsen-Bosman, Max Peters et autres
INTRODUCTION: Current pediatric-type diffuse high-grade glioma radiotherapy protocols apply a 1.0 cm clinical target volume (CTV) margin around the gross tumor volume (GTV). However, in adults with glioblastoma, large variations in GTV are observed during radiotherapy. The study aimed to map the …
nl, be
(code pays fourni par la source)
Accès ouvert
2020
conference-abstract
OpenAlex
Fatma E. El‐Khouly, Rianne Haumann, Marjolein Breur, Sophie E. M. Veldhuijzen van Zanten et autres
Abstract Diffuse intrinsic pontine glioma (DIPG) is a childhood brainstem tumor with a median overall survival of eleven months. Lack of chemotherapy efficacy may be related to an intact blood-brain-barrier (BBB). In this study we aim to compare the neuro-vascular unit (NVU) …
nl
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
C. Van Ommen, Laura van Iersel, MH Lequin, SC Clement et autres
Accès ouvert
2018
article
OpenAlex
Heleen Maurice‐Stam, Jan Pieter Marchal, Dannis G van Vuurden, William Peter Vandertop et autres
BACKGROUND: Adaptive behavior, i.e., the performance on daily activities required for personal and social independence, is essential to estimate in children with low-grade glioma (LGG) since most of them are long-term survivors. Our aim was to investigate adaptive behavior in children with …
nl, jp
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Stefan Rutkowski, Piergiorgio Modena, Daniel S. Williamson, Kornelius Kerl et autres
de, it, gb, dk, ca, fr, at, nl
(code pays fourni par la source)
2018
article
OpenAlex
Chrit T.W. Moonen, Dannis G van Vuurden
Accès ouvert
2017
article
OpenAlex
Fatma E. El‐Khouly, Dannis G van Vuurden, Thom Stroink, Esther Hulleman et autres
Despite decades of clinical trials for diffuse intrinsic pontine glioma (DIPG), patient survival does not exceed 10% at two years post-diagnosis. Lack of benefit from systemic chemotherapy may be attributed to an intact blood-brain-barrier (BBB). We aim to develop a theoretical model …
nl
(code pays fourni par la source)